Biotech Takes a Hit as Dealmakers Take a Knee in Q3

Biotech takes a hit as dealmakers take a knee in Q3

Endpoints News highlights DealForma’s latest Q3 2026 biopharma data and analysis, revealing a slowdown in M&A, licensing, and venture investment, alongside continued IPO activity and growing momentum in China-sourced deals. Read it here

DealForma Research

Explore More
Cancer R&D Partnerships, M&A, Venture Funding and IPO Activity - Q3 2026 Review

Cancer R&D Partnerships, M&A, Venture Funding and IPO Activity – Q3 2026 Review

Cardiovascular R&D Partnerships, M&A, Venture Funding and IPO Activity - Q3 2026 Review

Cardiovascular R&D Partnerships, M&A, Venture Funding and IPO Activity – Q3 2026 Review

Autoimmune R&D Partnerships, M&A, IPOs and Venture Funding - Q3 2026 Review

Autoimmune R&D Partnerships, M&A, IPOs and Venture Funding – Q3 2026 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive